TOKEN2049
8.9.2022 10:46:43 CEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced the DJ line-up of AFTER 2049, the official closing event of this year’s September edition. Headlined by Istanbul-based DJ and producer Carlita, electronic icon DJ Tennis, and Moojo, Mo-Shi and Leon (Calamar Crew), AFTER 2049 will be taking place on Friday, 30 September as it takes over the rooftop of the city's most iconic building, Marina Bay Sands.
Occupying both the iconic observation deck that offers unparalleled, uninterrupted views of the Singapore skyline, and CÉ LA VI, one of Singapore’s most iconic nightlife institutions, AFTER 2049 will be hosted in tandem with the first practice round of the Formula 1 Singapore Grand Prix 2022. The exclusive event will feature exhilarating views of the night race at what’s set to be the Singapore Grand Prix race weekend’s largest party.
Raphael Strauch, Founder of TOKEN2049 said: “AFTER 2049 is our way of thanking our community, partners and speakers who’ve supported us from day one. We’re thrilled to be bringing some of the biggest names in electronic music, while showcasing some of the rising stars in the region. Coming on the back of what’s going to be Asia’s largest crypto event with over 5,000 attendees, AFTER 2049 is set to raise the bar for nightlife events in Singapore and the broader Asia Pacific region.”
A limited number of tickets for AFTER 2049 will be sold via Resident Advisor from 13 September onwards.
TOKEN2049 Singapore marks the conference’s Singapore debut which runs from 28 to 29 September ahead of the Singapore Grand Prix race weekend. Sponsors of AFTER 2049 include Asia’s one-stop gateway to Web 3.0 and one of the region’s leading providers of non-custodial staking services RockX; core blockchain infrastructure company Parity Technologies; leading blockchain and digital currency-focused venture capital firm Cypher Capital; one-stop, cross-chain aggregator for decentralised finance and metaverse products XY Finance; Asia-based full-stack proprietary venture capital firm Newman Capital; and Singapore-based crypto unicorn and digital assets financial services platform Matrixport.
Attendees will be able to hear from some of the industry’s leading entrepreneurs and thought leaders on all aspects of the broader crypto and Web3 arena. As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
Additional sponsors for AFTER 2049 include leading South Korean game company Wemade; world’s largest cryptocurrency derivatives copy trade platform Bitget; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; digital asset exchange AAX; global online identity verification platform Trulioo; cryptocurrency and derivatives exchange OKX; decentralised and open-source protocol Syscoin; global digital assets exchange Zipmex; and collaborative Web3 credential infrastructure Galxe.
To purchase tickets for AFTER 2049, please visit: https://ra.co/events/1578263.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom